Cargando…

Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer

Detalles Bibliográficos
Autores principales:	Chau, Ian, Le, Dung T., Ott, Patrick A., Korytowsky, Beata, Le, Hannah, Le, T. Kim, Zhang, Ying, Sanchez, Teresa, Maglinte, Gregory A., Laurie, Melissa, Abraham, Pranav, Patel, Dhiren, Shangguan, Tong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942567/ https://www.ncbi.nlm.nih.gov/pubmed/31679092 http://dx.doi.org/10.1007/s10120-019-01021-y

Ejemplares similares

Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer
por: Chau, Ian, et al.
Publicado: (2019)

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2015)

A Comparison of Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving First-Line Therapy for Unresectable Advanced Gastric or Gastroesophageal Junction Cancer Versus Esophageal Adenocarcinomas
por: Shankaran, Veena, et al.
Publicado: (2020)

Missed Giant Lower Esophageal Leiomyoma in a Young Female Presenting with Refractory Gastroesophageal Reflux Disease
por: Quach, Duc Trong, et al.
Publicado: (2021)

Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers
por: Goff, Laura W., et al.
Publicado: (2014)

Surgical Treatment of Gastroesophageal Junction Cancer
por: Hashimoto, Tadayoshi, et al.
Publicado: (2018)

History of esophagectomy for cancer of the esophagus and the gastroesophageal junction
por: Lerut, Toni, et al.
Publicado: (2021)

The Incidence of Free Peritoneal Tumor Cells before and after Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer
por: Strandby, Rune B., et al.
Publicado: (2020)

Identification of Sensitivity Predictors of Neoadjuvant Chemotherapy for the Treatment of Adenocarcinoma of Gastroesophageal Junction
por: Li, Shoumiao, et al.
Publicado: (2017)

Circulating Tumor DNA in Gastric and Gastroesophageal Junction Cancer
por: Paschold, Lisa, et al.
Publicado: (2022)

Feature Review Papers on Gastroesophageal Junction and Gastric Cancers
por: Gronnier, Caroline
Publicado: (2022)

Two decades of gastric and gastroesophageal junction cancer surgery
por: Plum, Patrick S., et al.
Publicado: (2023)

Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada
por: Ding, Philip Q., et al.
Publicado: (2022)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Genetic Polymorphisms at TIMP3 Are Associated with Survival of Adenocarcinoma of the Gastroesophageal Junction
por: Bashash, Morteza, et al.
Publicado: (2013)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease
por: Lee, Yeong Yeh
Publicado: (2013)

Cancer of the oesophagus and gastroesophageal junction – a difficult clinical problem
por: Głuszek, Stanisław, et al.
Publicado: (2014)

Understanding the Challenges Faced by Esophageal and Gastroesophageal Junction Cancer Survivors
por: McGillivray, Erin, et al.
Publicado: (2023)

Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China
por: Shu, Yamin, et al.
Publicado: (2022)

Recent progress of chemotherapy and biomarkers for gastroesophageal cancer
por: Maeda, Osamu, et al.
Publicado: (2019)

Real‐world clinical outcomes of the combination of anti‐PD‐1 antibody, trastuzumab, and chemotherapy for HER2‐positive gastric/gastroesophageal junction cancer
por: Yang, Ju, et al.
Publicado: (2023)

Refractory gastroesophageal reflux disease
por: Subramanian, Charumathi Raghu, et al.
Publicado: (2015)

Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma
por: Anderegg, M. C. J., et al.
Publicado: (2017)

Neoadjuvant Chemoradiotherapy versus Chemotherapy for Gastroesophageal Junction Adenocarcinoma; Which Is the Optimal Treatment Option?
por: Zandirad, Eric, et al.
Publicado: (2022)

Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials
por: Zhao, Xin, et al.
Publicado: (2018)

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma: a cost-effectiveness analysis
por: Cao, Xueqiong, et al.
Publicado: (2023)

Gastroesophageal junction adenocarcinoma metastasizing to gingiva
por: Masamatti, Smita S, et al.
Publicado: (2013)

Epidemiology of Gastroesophageal Junction Adenocarcinoma in Korea
por: Kim, Jin-Jo
Publicado: (2018)

Cauda Equina Syndrome Secondary to Leptomeningeal Carcinomatosis of Gastroesophageal Junction Cancer
por: Alkhotani, Amal, et al.
Publicado: (2016)

The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma
por: Dinneen, Kate, et al.
Publicado: (2021)

Impact of Radiation Dose on Postoperative Complications in Esophageal and Gastroesophageal Junction Cancers
por: Kastelowitz, Noah, et al.
Publicado: (2021)

Prognostic Nomogram for Postoperative Patients With Gastroesophageal Junction Cancer of No Distant Metastasis
por: Guo, Qiang, et al.
Publicado: (2021)

Incidence and Dosimetric Predictors of Radiation-Induced Gastric Bleeding After Chemoradiation for Esophageal and Gastroesophageal Junction Cancer
por: Montovano, Margaret, et al.
Publicado: (2021)

Relevance of Position and Movement of the Gastroesophageal Junction in Gastroesophageal Reflux Disease: Author's Reply
por: Hong, Su Jin
Publicado: (2013)

Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction
por: Mingol, Fernando, et al.
Publicado: (2015)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort
por: Manfredi, Sylvain, et al.
Publicado: (2022)

Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
por: Charalampakis, Nikolaos, et al.
Publicado: (2022)

Trends in surgical techniques for the treatment of esophageal and gastroesophageal junction cancer: the 2022 update
por: de Groot, E M, et al.
Publicado: (2023)

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer
por: Muro, Kei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_96ku0ruhufj401ho1g6o6net89